Genmab — November 2020
-
-
Phase 3 Study of Epcoritamab for Advanced DLBCL to Open in Europe, Australia https://immuno-oncologynews.com/2020/11/18/phase-3-study-epcoritamab-in-relapsed-refractory-diffuse-large-b-cell-lymphoma-opening/?cn-reloaded=1
-
Torsdagens aviser med Tryg, Mærsk og Huscompagniet: https://www.proinvestor.com/investornyt/669735/torsdagens-aviser-med-tryg-maersk-og-huscompagniet
-
-
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Genmab (NASDAQ:GMAB) A/S on Thursday, setting a price target of $45
-
ImmunoPrecise and Genmab Enter into a Technology Partnership Targeting Infectious Disease https://ceo.ca/@newswire/immunoprecise-and-genmab-enter-into-a-technology-partnership
-
@E L the link is broken
-
And by the way you soon need a 3rd hand when counting GEN1046 expansion
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind